Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 17, 2005

View Archived Issues

Amyloidosis and renal disease progression

Q3 progress at Incyte

CombiMatrix and Novavax collaborate on technology for vaccine production

Financing at AM-Pharma to advance programs into phase II

Boehringer Ingelheim and Biolipox partner on drugs for pain and inflammation

Tolvaptan for autosomal dominant polycystic kidney disease

Endogenous stem cell activation for the treatment of Parkinson's

Treating glucose-deprived neurons ameliorates cognitive deficits and oxidative damage

Levosimendan reported effective in the treatment of ADHF

Synairgen begins phase I trial of IFN-beta to reduce asthma exacerbations

tgAAC-09 begins phase II study in South Africa

New approaches to pandemic influenza vaccine development

Phase I/II trial evaluates MGCD-0103 and azacitidine for MDS and AML

Welichem begins new initiatives with Chinese partners

Spectrum reports product development highlights of third quarter

New selective inhibitor of enterovirus replication for myocarditis

Antitumor effects of antibody-drug conjugate targeting glycoprotein NMB

NLNQ-1: a novel hypoxia-selective cytotoxin and radiosensitizer

EP4 agonism as a treatment for diabetic nephropathy

Ghrelin reverses endothelial function in patients with metabolic syndrome

New p38 MAPK inhibitor shows joint-protective effects in rat adjuvant-induced arthritis

Altana withdraws Daxas MAA

Novel FXR activator shows promise in the treatment of hepatic fibrosis

Recent patents describe novel anti-hepatitis agents

New CETP inhibitors disclosed in recent Merck & Co. patent

New treatments for neuropsychiatric disorders claimed in recent patent literature

Update on SCH-503034 in the treatment of hepatitis C

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...